| Adverse reactions, n (%) . | Whole telitacicept group (n = 42) . | Newly treated telitacicept subgroup (n = 20) . | Conventional IS group (n = 28) . | P-value . |
|---|---|---|---|---|
| Local skin reactions | 14 (33.3) | 7 (35.0) | ||
| Infection | 2 (4.8) | 1 (5.0) | 2 (7.1) | |
| Hair loss | 7 (25.0) | |||
| Skin acne | 4 (14.3) | |||
| Obesity | 4 (14.3) | |||
| Hand tremors | 2 (7.1) | |||
| Osteoporosis | 2 (7.1) | |||
| Fatigue | 1 (2.4) | 1 (5.0) | ||
| Incidence of AEs | 17 (40.5) | 9 (45.0) | 21 (75.0) | .035 |
| Adverse reactions, n (%) . | Whole telitacicept group (n = 42) . | Newly treated telitacicept subgroup (n = 20) . | Conventional IS group (n = 28) . | P-value . |
|---|---|---|---|---|
| Local skin reactions | 14 (33.3) | 7 (35.0) | ||
| Infection | 2 (4.8) | 1 (5.0) | 2 (7.1) | |
| Hair loss | 7 (25.0) | |||
| Skin acne | 4 (14.3) | |||
| Obesity | 4 (14.3) | |||
| Hand tremors | 2 (7.1) | |||
| Osteoporosis | 2 (7.1) | |||
| Fatigue | 1 (2.4) | 1 (5.0) | ||
| Incidence of AEs | 17 (40.5) | 9 (45.0) | 21 (75.0) | .035 |
P-value was the statistical difference between the newly treated telitacicept subgroup and the conventional IS group.
| Adverse reactions, n (%) . | Whole telitacicept group (n = 42) . | Newly treated telitacicept subgroup (n = 20) . | Conventional IS group (n = 28) . | P-value . |
|---|---|---|---|---|
| Local skin reactions | 14 (33.3) | 7 (35.0) | ||
| Infection | 2 (4.8) | 1 (5.0) | 2 (7.1) | |
| Hair loss | 7 (25.0) | |||
| Skin acne | 4 (14.3) | |||
| Obesity | 4 (14.3) | |||
| Hand tremors | 2 (7.1) | |||
| Osteoporosis | 2 (7.1) | |||
| Fatigue | 1 (2.4) | 1 (5.0) | ||
| Incidence of AEs | 17 (40.5) | 9 (45.0) | 21 (75.0) | .035 |
| Adverse reactions, n (%) . | Whole telitacicept group (n = 42) . | Newly treated telitacicept subgroup (n = 20) . | Conventional IS group (n = 28) . | P-value . |
|---|---|---|---|---|
| Local skin reactions | 14 (33.3) | 7 (35.0) | ||
| Infection | 2 (4.8) | 1 (5.0) | 2 (7.1) | |
| Hair loss | 7 (25.0) | |||
| Skin acne | 4 (14.3) | |||
| Obesity | 4 (14.3) | |||
| Hand tremors | 2 (7.1) | |||
| Osteoporosis | 2 (7.1) | |||
| Fatigue | 1 (2.4) | 1 (5.0) | ||
| Incidence of AEs | 17 (40.5) | 9 (45.0) | 21 (75.0) | .035 |
P-value was the statistical difference between the newly treated telitacicept subgroup and the conventional IS group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
